Clinical Trials Logo

Haemophilus Influenzae clinical trials

View clinical trials related to Haemophilus Influenzae.

Filter by:
  • None
  • Page 1

NCT ID: NCT01730391 Completed - Clinical trials for Neisseria Meningitidis

Neisseria Meningitidis Burden of Disease Study

Start date: January 2013
Phase: N/A
Study type: Observational

This study aims to provide an estimate of the proportion of suspected cases of bacterial meningitis that are due to N. meningitidis and the serogroup responsible in The Philippines and Vietnam.

NCT ID: NCT00849069 Terminated - Clinical trials for Streptococcus Pneumoniae

Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine

Start date: March 12, 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK2231395A candidate vaccine in adults and elderly adults with chronic obstructive pulmonary disease. Subjects will be vaccinated 3 times with an interval of respectively 2 and 10 months.

NCT ID: NCT00814489 Completed - Clinical trials for Streptococcus Pneumoniae

Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults

Start date: January 8, 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2 formulations of a non-typable Haemophilus influenzae and pneumococcal candidate vaccine in young adults. Subjects will be vaccinated 2 times in an observer-blind manner with an interval of 2 months. The subjects receiving Engerix-B will receive in an open-manner a third dose of the vaccine at Month 6. The protocol posting has been updated following a protocol amendment.

NCT ID: NCT00804284 Completed - Tetanus Clinical Trials

Database Surveillance Safety Study of PENTACEL® Vaccine

Start date: September 2008
Phase: N/A
Study type: Observational

The objective for this study is to characterize the safety profile of PENTACEL® vaccine for identification of potential vaccine-related adverse events not currently associated with PENTACEL® vaccine administration.